Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	129425-81-6
Formula :	C₁₄H₁₄O₅S
M.W :	294.32
SMILES Code :	O=C(O)CCC(C1=CC2=CC(OC)=C(OC)C=C2S1)=O
Synonyms :	5,6-dimethoxy-γ-oxo-benzo[b]thiophene-2-Butanoic Acid
MDL No. :	MFCD32640674
InChI Key :	APCLRHPWFCQIMG-UHFFFAOYSA-N
Pubchem ID :	23035251

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Bone marrow-derived macrophages (BMDM)	0.01 mg/ml	1 day	To assess the effect of MSA-2 on macrophage polarization, results showed MSA-2 significantly increased M1-like markers (CD86, H-2Kd) and proinflammatory cytokines (IFN-β, IL-6, TNF-α).	J Hematol Oncol. 2022 Oct 8;15(1):142.
Bone marrow-derived dendritic cells (BMDC)	0.01 mg/ml	1 day	To evaluate the effect of MSA-2 on STING pathway activation, results showed MSA-2 significantly upregulated DC maturation markers (CD80, CD86, H-2Kd, I-A/I-E) and proinflammatory cytokines (IFN-β, IL-6, TNF-α).	J Hematol Oncol. 2022 Oct 8;15(1):142.
THP-1 cells	20 µM	1 hour	Evaluate the activation effect of MSA-2 on the cGAS/STING signaling pathway in THP-1 cells	BMC Med. 2024 Mar 5;22(1):96.
D2.0R cells	10-50 µM	16-48 hours	To evaluate the effect of MSA-2 on NK cell killing of D2.0R cells, results showed MSA-2 significantly enhanced NK cell killing	Cancer Res. 2024 Oct 15;84(20):3337-3353.
Short-term expanded Vδ2 γδ T-cell lines	25 µM	24 hours	MSA-2 co-stimulated cytokine induction but induced cell death	Oncoimmunology. 2022 Feb 1;11(1):2030021.
Monocytes	25 µM	24 hours	MSA-2 stimulated IL-1β and TNF-α secretion and induced cell death	Oncoimmunology. 2022 Feb 1;11(1):2030021.
Vδ2 T cells	25 µM	24 hours	MSA-2 co-stimulated cytokine induction but inhibited proliferation	Oncoimmunology. 2022 Feb 1;11(1):2030021.
THP1 cells	40 µM	24 hours	To validate STING activation by SAProsome-3 in THP1 cells, results showed upregulation of IFN-β, TNF-α, and CXCL10 mRNA expression and activation of STING downstream signaling.	Nat Commun. 2023 Jul 31;14(1):4584.
Bone marrow-derived dendritic cells (BMDC)	40 µM	24 hours	To evaluate the STING pathway activation by SAProsomes, results showed significant upregulation of IFN-β, TNF-α, and CXCL10 mRNA expression and promotion of DC maturation.	Nat Commun. 2023 Jul 31;14(1):4584.
STING knockout PK-15 cells	30 µM	24 hours	To verify whether the antiviral effect of MSA-2 depends on STING, results showed MSA-2 failed to inhibit SVV replication in STING knockout cells.	Viruses. 2023 Oct 24;15(11):2138.
PK-15 cells	30 µM	24 hours	To evaluate the inhibitory effect of MSA-2 on SVV replication, results showed MSA-2 significantly reduced viral RNA levels and virus titers.	Viruses. 2023 Oct 24;15(11):2138.
RAW264.7 cells	10, 50 µM	24 hours	Evaluate the effect of MSA-2 and MSA-2-Pt on the secretion of IFN-β by RAW264.7 cells. The results showed that both could trigger the secretion of IFN-β.	ACS Omega. 2024 Jan 3;9(2):2650-2656.
MC38 cells	25, 50, 75, 100, 200, 300 µM	24 hours	Evaluate the effect of MSA-2 and MSA-2-Pt on the viability of MC38 cells. The results showed that MSA-2-Pt induced cell death significantly from 75 μM, showing a dose-dependent response, while MSA-2 did not cause cell death until 300 μM.	ACS Omega. 2024 Jan 3;9(2):2650-2656.
RAW264.7 cells	10, 25, 50 µM	3 hours	Evaluate the activation of the STING signaling pathway by MSA-2 and MSA-2-Pt. The results showed that both MSA-2-Pt and MSA-2 increased the levels of phosphorylated P65 (P-P65).	ACS Omega. 2024 Jan 3;9(2):2650-2656.
Mouse bone marrow-derived dendritic cells	10 µM MSA-2	30 min pretreatment followed by 2hours exposure to LLC-conditioned media	To assess the effect of STING agonist MSA-2 on Ch25h mRNA expression, results showed MSA-2 partially prevented tumor-conditioned media-induced downregulation of Ch25h mRNA	Nat Commun. 2022 Nov 4;13(1):6623.
MCF7 cells	35 µM	6 hours	To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance.	Nat Commun. 2025 Feb 14;16(1):1629.
A549 cells	35 µM	6 hours	To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance.	Nat Commun. 2025 Feb 14;16(1):1629.
CT26 cells	35 µM	6 hours	To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance.	Nat Commun. 2025 Feb 14;16(1):1629.
B16F10 cells	35 µM	6 hours	To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance.	Nat Commun. 2025 Feb 14;16(1):1629.

BALB/c mice	Metastatic dormancy model of breast cancer	Intraperitoneal injection	1 mg per dose	Single dose, 7 days post-inoculation	To evaluate the effect of MSA-2 on breast cancer metastatic dormancy, results showed a single dose significantly prolonged mouse survival time	Cancer Res. 2024 Oct 15;84(20):3337-3353.
Mice	Bilateral 4T1 tumor-bearing mice model	Intravenous injection	10 mg/kg	Single injection, observed for 21 days	Evaluated the inhibitory effect of AMFL on primary and distant tumors, showing that AMFL+NIR treatment significantly suppressed primary tumor growth and controlled distant tumor growth, improving survival rates.	J Am Chem Soc. 2025 Mar 5;147(9):7433-7444
C57BL/6 mice	MC38 colon carcinoma model and B16F10 melanoma model	Intratumoral injection	150 μg	Three doses	Evaluate the antitumor effect of MSA-2-Pt in MC38 and B16F10 tumor models. The results showed that MSA-2-Pt significantly reduced tumor growth and increased survival, with 7/9 mice tumor-free in the MC38 model and 2/10 mice tumor-free in the B16F10 model.	ACS Omega. 2024 Jan 3;9(2):2650-2656.
BALB/c mice	4T1 breast cancer model	Intravenous injection	2.4 mg/kg	Every 2 days for a total of 3 times	To evaluate the antitumor effect and immune activation of MSA-2 in vivo, results showed that MN NPs significantly inhibited tumor growth and promoted DC maturation and T-cell infiltration.	Biomater Res. 2024 Jul 4;28:0048
FVB mice	EGFR-mutant lung cancer model	Intraperitoneal injection	20 mg/kg	Every three days	Evaluate the effect of MSA-2 combined with osimertinib	Front Immunol. 2023 Feb 16;14:1077203
C57BL/6 mice	B16F10 tumor model	Orthotopic implantation	22.5 mg/kg	Single implantation, observed for 48 hours	To evaluate the antitumor immune response of MSA-2 in vivo, results showed that MSA-2 significantly increased intratumor levels of IFNβ and IFNγ, and promoted DC maturation and T cell infiltration.	Nat Commun. 2025 Feb 14;16(1):1629.
C57BL/6 mice	Subcutaneous MC38 colorectal tumor model	Intravenous injection	35 mg/kg	Administered on days 0, 4, and 8, total of 3 doses	To evaluate the antitumor efficacy of SAProsomes, results showed SAProsome-3 significantly inhibited tumor growth and induced 100% complete response rate.	Nat Commun. 2023 Jul 31;14(1):4584.
Mice	Subcutaneous LLC tumor model	Oral	40 mg/kg MSA-2 orally, 5 mg/kg anti-PD-1 antibody i.p.	Administered on day 4, 8, 12 and 16	To evaluate the anti-tumor efficacy of MSA-2 combined with anti-PD-1 therapy, results showed the combination significantly inhibited tumor growth and improved survival, which was dependent on CH25H expression	Nat Commun. 2022 Nov 4;13(1):6623.
Mice	B16, EMT-6, CT26, and H22 models	Oral	50 mg/kg	Single dose	To evaluate the antitumor activity of MSA-2 combined with YM101, results showed the combination therapy significantly inhibited tumor growth and prolonged mouse survival.	J Hematol Oncol. 2022 Oct 8;15(1):142.
Mice	U14 and TC-1 cervical cancer models	Oral	50 mg/kg	Single dose	To evaluate the inhibitory effect of MSA-2 alone or in combination with anti-PD-1 on the growth of subcutaneous cervical tumors. Results showed that MSA-2 significantly suppressed tumor growth and had a better effect when combined with anti-PD-1.	Front Immunol. 2024 Mar 14;15:1342647
Mice	B16F10 melanoma model	Intratumoral injection	500 µg/dose	Administered on days 1, 4, and 7	Evaluate the in vivo antitumor effect of DW18343, results showed DW18343 significantly inhibited tumor growth.	MedComm (2020). 2024 Dec 20;6(1):e70001
C57BL/6 mice	Pan02 pancreatic cancer model	Intravenous injection	every 2 days for 16 days	Every 2 days for 16 days	Evaluate the in vivo antitumor activity of MSA-2 and cisplatin conjugates, showing significant tumor growth inhibition and enhanced immune response.	Natl Sci Rev. 2024 Jan 17;11(1):nwae020

{[proInfo.proName]}

CAS No.: 129425-81-6

{[proInfo.proName]}

CAS No.: 129425-81-6

Alternative Products

Product Details of MSA-2

Safety of MSA-2

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed